论文部分内容阅读
沙格列汀(saxagliptin,1),化学名为(1S,3S,5S)-2-[(2S)-2-氨基-2-(3-羟基三环[3.3.1.13,7]癸烷)乙酰基]-2-氮杂双环[3.1.0]己烷-3-腈,是由百时美施贵宝和阿斯利康制药有限公司联合研发的二肽基肽酶-Ⅳ(DPP-Ⅳ)抑制剂,2009年经美国FDA批准上市,用于治疗2型糖尿病[1-3]。
Saxagliptin (1) has the chemical name (1S, 3S, 5S) -2 - [(2S) -2-amino- 2- (3- hydroxytricyclo [3.3.1.13,7] decane) Acetyl] -2-azabicyclo [3.1.0] hexane-3-carbonitrile, a dipeptidyl peptidase-IV (DPP-IV) inhibitor developed by Bristol- Myers and AstraZeneca Pharmaceutical Co. Agent, approved by the US FDA in 2009 for the treatment of type 2 diabetes [1-3].